This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Pain Therapeutics, Inc.
Drug Names(s): PTI-801
Description: Oxytrex is a combination of the opioid agonist oxycodone and a low dose of the opioid antagonist naltrexone. At usual doses, naltrexone blocks the action of the opioids. At a very low dose, however, it is believed to enhance pain relief and attenuate the development of tolerance or addiction through a separate pathway.
Deal Structure: In the first quarter of 2009, Pain Therapeutics discontinued the development of Oxytrex and reverted rights to this drug to Albert Einstein College of Medicine.
Additional information available to subscribers only: